Deep DiveEndocrine / Metabolic

Diabetes Management — Beyond the A1c

When the numbers look reasonable but the treatment plan doesn't.

LISTEN TO THIS DEEP DIVE14 min 6 sec
Diabetes Management — Beyond the A1c
0:00/0:00

Diabetes management becomes more complicated when the laboratory values, glucose patterns, and clinical picture stop telling the same story.

An A1c of 6.8% may represent excellent control in one patient and significant overtreatment in another. A patient with an A1c of 8.2% may need treatment intensification—or may already be receiving too much basal insulin. And a patient with an A1c at goal may still benefit from a medication change, not for additional glucose lowering, but for cardiovascular or renal protection.

The clinical question isn't simply whether glucose is controlled. It's whether the treatment is addressing the right problem, providing meaningful benefit, and avoiding unnecessary harm.

1 · Recognition & Interpretation

  • Consider two patients with identical A1c values of 7%. The first maintains relatively stable glucose concentrations throughout the day. The second experiences repeated overnight hypoglycemia followed by significant daytime hyperglycemia. Their A1c values may be identical, but their risk profiles are not.
  • A1c reflects average glycemic exposure. It does not reveal glucose variability, the frequency of hypoglycemia, or when excursions occur. This is where continuous glucose monitoring changes the assessment.
  • For many nonpregnant adults, commonly used CGM targets include: time in range (70–180 mg/dL) greater than 70%; time below 70 mg/dL less than 4%; time below 54 mg/dL less than 1%. These are general targets, not universal treatment mandates. Older adults and patients with substantial hypoglycemia risk may need more conservative goals.
  • The more useful clinical question is often what happens outside the target range. Is glucose rising consistently after one meal? Falling overnight? Remaining elevated despite a seemingly adequate insulin regimen? Each pattern suggests a different management problem.
  • When A1c and CGM-derived glucose estimates disagree, don't automatically assume one is correct. Evaluate sensor accuracy and data sufficiency, then consider conditions affecting red blood cell turnover, anemia, kidney disease, transfusion history, or hemoglobin variants that can alter A1c interpretation.

Clinical pearl: When fasting glucose is controlled but A1c remains elevated, don't automatically increase basal insulin. Identify where the remaining hyperglycemia occurs.

2 · Differential & Workup

  • One of the more common management traps is treating every elevated A1c as evidence that more basal insulin is needed. Consider a patient with Type 2 diabetes receiving 54 units of insulin glargine nightly. Their fasting glucose generally runs between 95 and 115 mg/dL, but their A1c remains 8.4%.
  • Basal insulin principally addresses hepatic glucose production between meals and overnight. If fasting glucose is already controlled, additional basal insulin may create nocturnal hypoglycemia without adequately addressing postprandial hyperglycemia. This is overbasalization: continuing to escalate basal insulin beyond what is clinically needed rather than addressing the remaining glucose excursions.
  • Clues to overbasalization include a substantial bedtime-to-morning glucose decline, hypoglycemia, marked glycemic variability, or persistently elevated postprandial glucose despite fasting values at goal. A bedtime-to-morning decline of approximately 50 mg/dL or more is one potential warning sign, not a standalone diagnostic cutoff.
  • Persistent hyperglycemia may also reflect missed doses, injection-technique problems, lipohypertrophy, medication access barriers, inconsistent carbohydrate intake, intercurrent illness, glucocorticoid exposure, or progressive insulin deficiency. In patients whose clinical course does not fit typical Type 2 diabetes, reconsider whether the underlying diagnosis is correct.
  • A treatment decision should start with a more complete assessment than the most recent A1c. Review glucose trends, time below range, medication administration, changes in weight, renal function, and symptoms suggesting insulin deficiency. For patients using CGM, examine the ambulatory glucose profile rather than relying solely on the average glucose or glucose management indicator.
  • For patients using insulin pumps, unexplained sustained hyperglycemia raises concern for infusion-set failure, interrupted insulin delivery, or ineffective insulin absorption. In patients with Type 1 diabetes, interrupted rapid-acting insulin delivery can produce clinically important insulin deficiency and ketosis within hours. A patient with unexplained hyperglycemia, nausea, vomiting, or illness may require ketone assessment and urgent evaluation rather than simply another correction bolus.

3 · Treatment & Management

Contemporary diabetes management has moved beyond selecting medications exclusively according to their glucose-lowering potency. For Type 2 diabetes, established cardiovascular disease, heart failure, chronic kidney disease, obesity, hypoglycemia risk, and treatment burden can change which therapy provides the greatest benefit. Consider three patients with similar A1c values.

Patient A: Type 2 diabetes with established atherosclerotic cardiovascular disease

A GLP-1 receptor agonist with demonstrated cardiovascular benefit may be an important part of the treatment strategy, even when additional glucose lowering is not the primary concern. An SGLT2 inhibitor with demonstrated benefit may also be appropriate depending on the patient's overall risk profile.

Patient B: Type 2 diabetes with heart failure

An SGLT2 inhibitor with demonstrated heart failure benefit becomes a priority because it can reduce heart failure hospitalization risk independently of A1c. In a patient with obesity and symptomatic HFpEF, selected GLP-1–based therapies may provide additional benefits.

Patient C: Type 2 diabetes with CKD and albuminuria

Kidney protection becomes a major treatment objective. An SGLT2 inhibitor with demonstrated renal benefit is generally recommended when kidney function and other clinical factors permit, with GLP-1 receptor agonists offering additional options for glycemic, cardiovascular, and renal risk management.

SGLT2 inhibitors and declining eGFR

A medication can have diminishing glucose-lowering effects as eGFR declines while retaining clinically meaningful kidney and cardiovascular benefits. Glycemic efficacy decreases substantially at lower eGFR values, particularly below approximately 45 mL/min/1.73 m². Yet selected agents may still be initiated for kidney protection at an eGFR of at least 20 mL/min/1.73 m², depending on the indication and prescribing guidance.

Medication considerations

  • SGLT2 inhibitor risks: These agents provide substantial cardiorenal benefits in appropriately selected patients, but they also increase the risk of ketoacidosis, including euglycemic diabetic ketoacidosis. A patient taking an SGLT2 inhibitor may develop clinically significant ketoacidosis without the marked hyperglycemia traditionally associated with DKA. This becomes especially relevant during acute illness, prolonged fasting, surgery, dehydration, or reduced insulin availability. SGLT2 inhibitors generally require interruption before scheduled surgery—typically three to four days, depending on the agent—and during certain acute illnesses or prolonged fasting.
  • GLP-1–based therapy considerations: These therapies may offer meaningful glycemic and weight benefits, but gastrointestinal intolerance, dehydration, suspected gastroparesis, and certain other clinical conditions can complicate treatment. When adding these therapies to insulin or a sulfonylurea regimen, clinicians should reassess medications that increase hypoglycemia risk rather than simply layering on another glucose-lowering agent.
  • For appropriate patients with Type 2 diabetes not already receiving one, adding a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist may be preferable to immediately adding prandial insulin. Other patients will require mealtime insulin, particularly when insulin deficiency or the degree of hyperglycemia makes it necessary.

Clinical pearl: An A1c at goal does not mean the diabetes regimen is optimized for cardiovascular and renal protection.

4 · Monitoring & Expected Response

  • Consider an older adult with Type 2 diabetes, CKD, and a recent A1c decline from 7.8% to 6.1%. On paper, the result looks impressive. But the patient has experienced reduced appetite, several episodes of dizziness, and occasional early-morning glucose readings in the 50s. They are still receiving the same insulin and sulfonylurea regimen.
  • This is not necessarily successful treatment. It may represent overtreatment. Declining kidney function can reduce insulin clearance and increase susceptibility to hypoglycemia. Reduced oral intake and continued insulin secretagogue use can further increase risk.
  • The appropriate clinical response may involve de-intensifying treatment, simplifying the regimen, and establishing safer individualized goals. This is particularly important in patients with frailty, cognitive impairment, limited life expectancy, recurrent hypoglycemia, or substantial treatment burden.
  • The objective is not to abandon glucose management. It is to recognize when the risks of aggressive treatment exceed the expected benefits.

5 · Intensification & De-intensification

  • Intensify treatment when individualized glycemic goals remain unmet after reviewing adherence, glucose patterns, and contributing factors. Examine the pattern before escalating: fasting hyperglycemia, postprandial excursions, and recurrent hypoglycemia each point toward different adjustments.
  • For patients with Type 2 diabetes not at goal on basal insulin alone, consider whether the remaining hyperglycemia is postprandial before increasing basal dose. Adding a GLP-1–based therapy or prandial insulin may be more appropriate than further basal escalation.
  • De-intensification is active clinical management, not a failure of treatment. Recurrent hypoglycemia, declining kidney function, reduced oral intake, frailty, cognitive impairment, or a shift in treatment goals are all indications to simplify or reduce the regimen.
  • Healthy older adults may have goals similar to younger adults. For selected older adults with multiple comorbidities, functional limitations, or limited life expectancy, less aggressive targets reduce hypoglycemia risk without meaningful loss of benefit.

Clinical pearl: A lower A1c is not automatically a better outcome. Sometimes the most appropriate treatment adjustment is to prescribe less.

6 · Escalation & Red Flags

  • Persistent marked hyperglycemia accompanied by vomiting, abdominal pain, dehydration, altered mental status, or abnormal breathing requires prompt evaluation for a hyperglycemic crisis.
  • In patients with Type 1 diabetes or significant insulin deficiency, missed basal insulin or interrupted pump delivery raises particular concern for DKA. For patients taking SGLT2 inhibitors, ketoacidosis must remain on the differential even when glucose is only mildly elevated.
  • Nausea, vomiting, abdominal pain, tachypnea, and unexplained metabolic acidosis should prompt consideration of DKA even when glucose is not dramatically elevated. SGLT2-associated euglycemic DKA can occur without the marked hyperglycemia traditionally expected.
  • Severe hypoglycemia requiring assistance, recurrent clinically significant hypoglycemia, or impaired awareness also warrants urgent reassessment of treatment safety.
  • In patients whose diabetes has been labeled Type 2, unexpected weight loss, ketosis, rapidly progressive hyperglycemia, or unusually early insulin dependence should prompt reconsideration of the diagnosis, including possible autoimmune diabetes or another insulin-deficient state. Management should follow the patient's clinical stability, degree of insulin deficiency, and underlying physiology—not simply the diagnostic label.

Clinical Pearls

Clinical Pearls

  • A1c Is Not the Whole PictureA1c reflects average glycemia, but it can conceal hypoglycemia and significant glucose variability. Review glucose patterns, time in range when available, and clinical context before changing therapy.
  • Treat the Pattern, Not Just the NumberFasting and postprandial hyperglycemia may require different interventions. Identify when glucose elevations occur before escalating medication or adjusting insulin.
  • Choose Medications Beyond Glycemic ControlIn appropriate patients, SGLT2 inhibitors and GLP-1 receptor agonists may offer cardiovascular, kidney, or weight-related benefits beyond A1c reduction. Match therapy to comorbidities, indications, contraindications, and individual risk.
  • Recognize Euglycemic DKAPatients taking SGLT2 inhibitors can develop diabetic ketoacidosis without marked hyperglycemia. Consider DKA when compatible symptoms or metabolic acidosis occur, even when glucose is not substantially elevated.
  • Individualize Treatment IntensityA lower A1c is not automatically a better outcome. In patients with recurrent hypoglycemia, frailty, or excessive treatment burden, de-intensification may be safer than additional medication.
  • Reassess the Treatment StrategyPersistent hyperglycemia does not always mean the patient needs more medication. Reevaluate adherence, medication access, glucose patterns, renal function, adverse effects, and whether the current regimen addresses the underlying problem.

Bottom Line

Effective diabetes management is not about achieving the lowest possible A1c. Interpret glucose patterns in context, choose therapies for benefits beyond glycemic control when appropriate, and recognize when treatment should be intensified—or de-intensified. The numbers guide the decision; the patient's physiology, comorbidities, and clinical circumstances determine the next step.

EVIDENCE & REFERENCES

  1. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S1–S352. doi:10.2337/dc25-SINT
  2. ElSayed NA, et al. Glycemic Targets: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl 1):S111–S125. doi:10.2337/dc25-S006
Back to Deep Dives